000218408 000__ 01527cam\a2200325Ia\45e0
000218408 001__ 218408
000218408 005__ 20220217104119.0
000218408 008__ 990630s1999\\\\dcua\\\\\b\\\f000\0\eng\d
000218408 020__ $$a0160581842
000218408 035__ $$a(OCoLC)41120531
000218408 035__ $$a218408
000218408 040__ $$aGPO$$cGPO$$dISE
000218408 043__ $$an-us---
000218408 049__ $$aISEA
000218408 074__ $$a1016-A
000218408 074__ $$a1016-B (MF)
000218408 0860_ $$aY 4.G 74/7:IS 7
000218408 088__ $$aSerial no. 105-182 (United States. Congress. House. Committee on Government Reform and Oversight)
000218408 1101_ $$aUnited States.$$bCongress.$$bHouse.$$bCommittee on Government Reform and Oversight.$$bSubcommittee on National Security, International Affairs, and Criminal Justice.
000218408 24510 $$aCutting edge issues in drug testing and drug treatment :$$bhearing before the Subcommittee on National Security, International Affairs, and Criminal Justice of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, second session, June 5, 1998.
000218408 260__ $$aWashington :$$bU.S. G.P.O. :$$bFor sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office,$$c1999.
000218408 300__ $$aiii, 177 p. :$$bill. ;$$c23 cm.
000218408 500__ $$aDistributed to some depository libraries in microfiche.
000218408 500__ $$aShipping list no.: 99-0178-P.
000218408 500__ $$a"Serial no. 105-182."
000218408 504__ $$aIncludes bibliographical references.
000218408 650_0 $$aEmployees$$xDrug testing$$zUnited States.
000218408 650_0 $$aDrug testing$$zUnited States.
000218408 650_0 $$aDrug abuse$$xTreatment$$zUnited States.
000218408 85230 $$bdfich$$hY 4.G 74/7:$$iIS 7
000218408 909CO $$ooai:library.usi.edu:218408$$pGLOBAL_SET
000218408 980__ $$aBIB
000218408 980__ $$aGOV RESOURCE
000218408 994__ $$aE0$$bISE